Engineered anti-toxin antibodies improve efficacy

The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent studies suggest that the constant region (Fc) of antibodies also influence efficacy.

In this issue of the Journal of Clinical Investigation, Jeffrey Ravetch and colleagues at The Rockefeller University demonstrate that engineering the Fc domain of anti-toxin antibodies increases toxin neutralization activity through enhancing the interaction between toxin-targeting antibodies and the Fc receptor on . The authors found that mice expressing humanized FcR were better protected from anthrax toxin when given engineered anti-anthrax toxin antibodies.

This study suggests that engineering the Fc domains of antibodies can be used as a strategy to enhance antibody efficacy.


Explore further

Liver tropism is key for B cell deletion immunotherapy

More information: Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity, J Clin Invest. DOI: 10.1172/JCI72676
Citation: Engineered anti-toxin antibodies improve efficacy (2014, January 9) retrieved 23 May 2019 from https://medicalxpress.com/news/2014-01-anti-toxin-antibodies-efficacy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more